Prudential Financial
GNMK

Prudential Financial’s GenMark Diagnostics, Inc GNMK Stock Holding History

Prudential Financial’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21,702
Closed -$141K – 2507
2019
Q2 		$141K Buy
+21,702
New +$153K ﹤0.01% 2377

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prudential Financial's GNMK Position: Q3 2019 in Review

Prudential Financial sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2019, closing a stake of 21,702 shares — an estimated $141K sold.

Prudential Financial first reported a position in GNMK in Q2 2019 and held it in 1 quarter. The position peaked at $141K in Q2 2019. 110 funds tracked by Wall St. Rank hold GNMK as of Q3 2019.

  • Prudential Financial reported no remaining GenMark Diagnostics, Inc position as of Q3 2019 after selling out during the quarter.
  • Prudential Financial sold 21,702 GenMark Diagnostics, Inc shares in Q3 2019, an estimated $141K.
  • Prudential Financial first reported a position in GenMark Diagnostics, Inc in Q2 2019 and held it in 1 quarter.
  • Prudential Financial's GenMark Diagnostics, Inc position peaked at $141K in Q2 2019.
  • 110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2019.

Based on Prudential Financial's 13F filing for Q3 2019, filed 13 Nov 2019.